AIMS: To examine the association between rosuvastatin and VTE risk, and whether effects vary in different subpopulations stratified by key demographic, cardiovascular disease (CVD) risk factors, and other risk factors associated with VTE. METHODS AND RESULTS: An individual participant data meta-analysis was conducted across two randomized controlled trials in 30 507 participants over a mean follow-up of 3.62 years, individuals had no prior history of vascular disease but were at intermediate CV risk. In both trials, participants were randomized to receive rosuvastatin or matching placebo. The primary outcome was VTE during follow-up, defined as either deep vein thrombosis or pulmonary embolism. Associations between rosuvastatin and VTE were examined in the overall pooled cohort, and subpopulations stratified by demographic risk factors (i.e. age and sex), CVD risk factors (i.e. obesity, smoking, lipid levels, blood pressure levels, and C-reactive protein level), and a history of cancer. Mean age was 65.96 (SD 7.19) years of age, and 17 832 (58.45%) were male and 5434 (17.82%) were smokers, median BMI was 27.6 [interquartile range (IQR) 24.7-31.1] kg/m2, and median CRP level was 3.4 (IQR 2.1-6.0) mg/L. There were 139 VTE events. In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75). No significant interactions were observed between treatment with rosuvastatin and the risk of VTE across subpopulations stratified by demographic, CVD risk factors, or a history of cancer (P-values for interactions >0.05 for all subgroups). CONCLUSION: Rosuvastatin is associated with a 47% proportional reduction in the risk of VTE, and its effect is consistent both in the presence or absence of VTE-related clinical risk factors. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To examine the association between rosuvastatin and VTE risk, and whether effects vary in different subpopulations stratified by key demographic, cardiovascular disease (CVD) risk factors, and other risk factors associated with VTE. METHODS AND RESULTS: An individual participant data meta-analysis was conducted across two randomized controlled trials in 30 507 participants over a mean follow-up of 3.62 years, individuals had no prior history of vascular disease but were at intermediate CV risk. In both trials, participants were randomized to receive rosuvastatin or matching placebo. The primary outcome was VTE during follow-up, defined as either deep vein thrombosis or pulmonary embolism. Associations between rosuvastatin and VTE were examined in the overall pooled cohort, and subpopulations stratified by demographic risk factors (i.e. age and sex), CVD risk factors (i.e. obesity, smoking, lipid levels, blood pressure levels, and C-reactive protein level), and a history of cancer. Mean age was 65.96 (SD 7.19) years of age, and 17 832 (58.45%) were male and 5434 (17.82%) were smokers, median BMI was 27.6 [interquartile range (IQR) 24.7-31.1] kg/m2, and median CRP level was 3.4 (IQR 2.1-6.0) mg/L. There were 139 VTE events. In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75). No significant interactions were observed between treatment with rosuvastatin and the risk of VTE across subpopulations stratified by demographic, CVD risk factors, or a history of cancer (P-values for interactions >0.05 for all subgroups). CONCLUSION: Rosuvastatin is associated with a 47% proportional reduction in the risk of VTE, and its effect is consistent both in the presence or absence of VTE-related clinical risk factors. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Sara Biere-Rafi; Barbara A Hutten; Alessandro Squizzato; Walter Ageno; Patrick C Souverein; Anton de Boer; Victor E A Gerdes; Harry R Büller; Pieter W Kamphuisen Journal: Eur Heart J Date: 2013-02-08 Impact factor: 29.983
Authors: Kazem Rahimi; Neeraj Bhala; Pieter Kamphuisen; Jonathan Emberson; Sara Biere-Rafi; Vera Krane; Michele Robertson; John Wikstrand; John McMurray Journal: PLoS Med Date: 2012-09-18 Impact factor: 11.069
Authors: John Gregson; Stephen Kaptoge; Thomas Bolton; Lisa Pennells; Peter Willeit; Stephen Burgess; Steven Bell; Michael Sweeting; Eric B Rimm; Christopher Kabrhel; Bengt Zöller; Gerd Assmann; Vilmundur Gudnason; Aaron R Folsom; Volker Arndt; Astrid Fletcher; Paul E Norman; Børge G Nordestgaard; Akihiko Kitamura; Bakhtawar K Mahmoodi; Peter H Whincup; Matthew Knuiman; Veikko Salomaa; Christa Meisinger; Wolfgang Koenig; Maryam Kavousi; Henry Völzke; Jackie A Cooper; Toshiharu Ninomiya; Edoardo Casiglia; Beatriz Rodriguez; Yoav Ben-Shlomo; Jean-Pierre Després; Leon Simons; Elizabeth Barrett-Connor; Cecilia Björkelund; Marlene Notdurfter; Daan Kromhout; Jackie Price; Susan E Sutherland; Johan Sundström; Jussi Kauhanen; John Gallacher; Joline W J Beulens; Rachel Dankner; Cyrus Cooper; Simona Giampaoli; Jason F Deen; Agustín Gómez de la Cámara; Lewis H Kuller; Annika Rosengren; Peter J Svensson; Dorothea Nagel; Carlos J Crespo; Hermann Brenner; Juan R Albertorio-Diaz; Robert Atkins; Eric J Brunner; Martin Shipley; Inger Njølstad; Deborah A Lawlor; Yvonne T van der Schouw; Randi Marie Selmer; Maurizio Trevisan; W M Monique Verschuren; Philip Greenland; Sylvia Wassertheil-Smoller; Gordon D O Lowe; Angela M Wood; Adam S Butterworth; Simon G Thompson; John Danesh; Emanuele Di Angelantonio; Tom Meade Journal: JAMA Cardiol Date: 2019-02-01 Impact factor: 14.676
Authors: Shmeylan Al Harbi; Raed Kensara; Ohoud Aljuhani; Ghazwa B Korayem; Ali F Altebainawi; Abdullah Al Harthi; Ramesh Vishwakarma; Alaa M Alenazi; Abdulmajed Almutairi; Omar Alshaya; Sultan Alraddadi; Tareq Al Sulaiman; Latifah Aldakkan; Reem Mahboob; Kholoud Alaamer; Abdulrahman Alissa; Awatif Hafiz; Nada Aldhayyan; Sara Althewaibi; Farhan Alenezi; Nadeen Y Alkhotani; Sara A Alghamdi; Abeer A Alenazi; Khalid Al Sulaiman Journal: Clin Appl Thromb Hemost Date: 2022 Jan-Dec Impact factor: 3.512